

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 14, 2018

**APOLLO MEDICAL HOLDINGS, INC.**

(Exact name of registrant as specified in its charter)

Delaware  
(State or Other Jurisdiction  
of Incorporation)

001-37392  
(Commission File  
Number)

46-3837784  
(I.R.S. Employer  
Identification Number)

1668 S. Garfield Avenue, 2nd Floor, Alhambra, CA 91801  
(Address of principal executive offices) (zip code)

(626) 282-0288  
(Registrant's telephone number, including area code)

N/A  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Precommencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Precommencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 2.02 Results of Operations and Financial Condition.**

On November 14, 2018, Apollo Medical Holdings, Inc. issued a press release, announcing its results of operations for the quarter ended September 30, 2018. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.

In accordance with General Instruction B.2 of Form 8-K, the information furnished pursuant to this Item 2.02, including Exhibit 99.1 furnished herewith, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements And Exhibits**

(d) Exhibits.

| <b>Exhibit No.</b> | <b>Description</b>  |
|--------------------|---|
| <u>99.1</u>        | <u>Press Release of Apollo Medical Holdings, Inc., dated November 14, 2018.</u> |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**APOLLO MEDICAL HOLDINGS, INC.**

Dated: November 14, 2018

By: /s/ Thomas S. Lam, M.D.

Name: Thomas S. Lam, M.D.

Title: Co-Chief Executive Officer

---

**APOLLO MEDICAL HOLDINGS REPORTS 72% REVENUE INCREASE YEAR OVER YEAR FOR THE THIRD QUARTER OF 2018**

*Alhambra, CA and Glendale, CA – (PR Newswire) – November 14, 2018* – Apollo Medical Holdings, Inc. (“ApolloMed” or “the Company”) (NASDAQ: AMEH), an integrated population health management company, today announced its consolidated 3<sup>rd</sup> Quarter financial results for the three and nine months ended September 30, 2018.

**Financial Highlights for the Three Months Ended September 30, 2018 Compared to the Three Months Ended September 30, 2017 (unaudited):**

- Total revenue of \$167.3 million for the three months ended September 30, 2018 as compared to total revenue of \$97.1 million in the comparable period of 2017, an increase of 72%.
  - Income from operations of \$56.6 million for the three months ended September 30, 2018 as compared to \$21.3 million in the comparable period of 2017, an increase of 166%.
  - Net income attributable to Apollo Medical Holdings, Inc. of \$9.1 million for the three months ended September 30, 2018 as compared to \$5.6 million in the comparable period of 2017, an increase of 62%.
  - As of September 30, 2018, the Company had total assets of \$551.9 million, including cash and cash equivalents of \$119.8 million.
-

“We are very pleased with our performance in the 3<sup>rd</sup> quarter, as the team maintained strong momentum and delivered outstanding results,” stated Eric Chin, Chief Financial Officer of ApolloMed. “Highlights of this quarter include net revenue increases of 72% year-over-year, net income attributable to Apollo Medical Holdings, Inc. increase of 62% year-over-year and quarterly net income attributable to Apollo Medical Holdings, Inc. increase of 242% when compared to our 2<sup>nd</sup> quarter of 2018, as well as a solid balance sheet.”

“We are very pleased with the progress of our long-term growth initiatives, especially with our continued organic revenue growth,” stated Warren Hosseinian, M.D., Co-Chief Executive Officer of ApolloMed. “We believe the strength and differentiation of our population health management platform provides us with the foundation to deliver sustainable, long-term shareholder value.”

“The healthcare industry is rapidly shifting to a risk-based, accountable care model, a model which we have been executing on for many years,” stated Thomas Lam, M.D., Co-Chief Executive Officer of ApolloMed. “We have full confidence in our strategy, our team and our company to succeed in this changing environment.”

“We continue to successfully execute on our growth strategies, leveraging our strong reputation as a trusted partner to all stakeholders in the care continuum,” stated Kenneth Sim, M.D., Executive Chairman of ApolloMed. “By consistently delivering excellent inpatient and outpatient services for our patients and our hospital, health plan and IPA partners, we believe we are well positioned for continued growth for the rest of this year and in 2019.”

For more details on ApolloMed’s September 30, 2018 quarter end results, please refer to the Company’s Quarterly Report on Form 10-Q to be filed with the U.S. Securities Exchange Commission (“SEC”) and accessible at [www.sec.gov](http://www.sec.gov).

---

**APOLLO MEDICAL HOLDINGS, INC.**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
**(UNAUDITED)**

|  | <u>September 30,</u><br><u>2018</u> | <u>December 31,</u><br><u>2017</u> |
|--|-------------------------------------|------------------------------------|
| <b>Assets</b>  |                                     |                                    |
| <b>Current assets</b>  |                                     |                                    |
| Cash and cash equivalents  | \$ 119,779,499                      | \$ 99,749,199                      |
| Restricted cash – short-term   | 4,218,176                           | 18,005,661                         |
| Fiduciary cash   | 3,434,409                           | 2,017,437                          |
| Investment in marketable securities  | 1,141,890                           | 1,143,095                          |
| Receivables, net   | 70,084,171                          | 20,117,304                         |
| Prepaid expenses and other current assets  | 4,175,308                           | 3,126,866                          |
| <b>Total current assets</b>  | <u>202,833,453</u>                  | <u>144,159,562</u>                 |
| <b>Noncurrent assets</b>   |                                     |                                    |
| Land, property and equipment, net  | 12,909,206                          | 13,814,306                         |
| Intangible assets, net   | 90,762,980                          | 103,533,558                        |
| Goodwill   | 189,604,746                         | 189,847,202                        |
| Loans receivable – related parties   | 7,500,000                           | 5,000,000                          |
| Loan receivable  | 5,000,000                           | 10,000,000                         |
| Investment in a privately held entity that does not report net asset value per share | 405,000                             | -                                  |
| Investments in other entities – equity method  | 24,122,895                          | 21,903,524                         |
| Investment in joint venture – equity method  | 16,673,840                          | -                                  |
| Restricted cash – long-term  | 745,412                             | 745,235                            |
| Other assets   | 1,341,337                           | 1,632,406                          |
| <b>Total noncurrent assets</b>   | <u>349,065,416</u>                  | <u>346,476,231</u>                 |
| <b>Total assets</b>  | <u>\$ 551,898,869</u>               | <u>\$ 490,635,793</u>              |

**APOLLO MEDICAL HOLDINGS, INC.**  
**CONDENSED CONSOLIDATED BALANCE SHEETS (Continued)**  
**(UNAUDITED)**

|  | <u>September 30,<br/>2018</u> | <u>December 31,<br/>2017</u> |
|--|-------------------------------|------------------------------|
| <b>Liabilities, Mezzanine Equity and Stockholders' Equity</b>  |                               |                              |
| <b>Current liabilities</b>   |                               |                              |
| Lines of credit, short-term  | \$ -                          | \$ 5,025,000                 |
| Accounts payable and accrued expenses  | 44,974,805                    | 13,279,620                   |
| Incentives payable   | 5,000,000                     | 21,500,000                   |
| Fiduciary accounts payable   | 3,434,409                     | 2,017,437                    |
| Medical liabilities  | 33,505,423                    | 63,972,318                   |
| Income taxes payable   | 1,285,653                     | 3,198,495                    |
| Bank loan  | 159,906                       | 510,391                      |
| Dividends payable  | 3,784,088                     | -                            |
| Capital lease obligations  | 100,982                       | 98,738                       |
| Total current liabilities  | <u>92,245,266</u>             | <u>109,601,999</u>           |
| <b>Noncurrent liabilities</b>  |                               |                              |
| Lines of credit, long-term   | 13,000,000                    | -                            |
| Deferred tax liability   | 34,651,670                    | 24,916,598                   |
| Liability for unissued equity shares   | 1,185,025                     | 1,185,025                    |
| Dividends payable  | -                             | 18,000,000                   |
| Capital lease obligations, net of current portion  | 542,982                       | 619,001                      |
| Total noncurrent liabilities   | <u>49,379,677</u>             | <u>44,720,624</u>            |
| <b>Total liabilities</b>   | <u>141,624,943</u>            | <u>154,322,623</u>           |
| <b>Commitments and Contingencies</b>   |                               |                              |
| <b>Mezzanine equity</b>  |                               |                              |
| Noncontrolling interest in Allied Pacific of California IPA ("APC")  | <u>225,147,257</u>            | <u>172,129,744</u>           |
| <b>Stockholders' equity</b>  |                               |                              |
| Series A Preferred stock, par value \$0.001; 5,000,000 shares authorized (inclusive of Series B Preferred stock); 1,111,111 issued and zero outstanding  | -                             | -                            |
| Series B Preferred stock, par value \$0.001; 5,000,000 shares authorized (inclusive of Series A Preferred stock); 555,555 issued and zero outstanding  | -                             | -                            |
| Common stock, par value \$0.001; 100,000,000 shares authorized, 33,025,189 and 32,304,876 shares outstanding, excluding 1,682,110 treasury shares held by APC, at September 30, 2018 and December 31, 2017, respectively | 33,025                        | 32,305                       |
| Additional paid-in capital   | 162,810,695                   | 158,181,192                  |
| Retained earnings  | 17,100,065                    | 1,734,531                    |
|  | <u>179,943,785</u>            | <u>159,948,028</u>           |
| Noncontrolling interest  | <u>5,182,884</u>              | <u>4,235,398</u>             |
| Total stockholders' equity   | <u>185,126,669</u>            | <u>164,183,426</u>           |
| <b>Total liabilities, mezzanine equity and stockholders' equity</b>  | <u>\$ 551,898,869</u>         | <u>\$ 490,635,793</u>        |

**APOLLO MEDICAL HOLDINGS, INC.**  
**CONDENSED CONSOLIDATED STATEMENTS OF INCOME**  
(UNAUDITED)

|  | Three Months Ended<br>September 30, |                     | Nine Months Ended<br>September 30, |                      |
|--|-------------------------------------|---------------------|------------------------------------|----------------------|
|  | 2018                                | 2017                | 2018                               | 2017                 |
| <b>Revenue</b>   |                                     |                     |                                    |                      |
| Capitation, net  | \$ 90,612,720                       | \$ 66,130,166       | \$ 266,834,186                     | \$ 193,725,886       |
| Risk pool settlements and incentives                                 | 57,788,932                          | 21,498,540          | 89,641,885                         | 40,994,338           |
| Management fee income  | 12,851,178                          | 6,449,329           | 37,297,358                         | 19,274,141           |
| Fee-for-service, net   | 5,665,053                           | 2,729,295           | 19,092,631                         | 8,437,756            |
| Other income   | 362,527                             | 326,951             | 1,585,623                          | 1,349,922            |
| <b>Total revenue</b>   | <u>167,280,410</u>                  | <u>97,134,281</u>   | <u>414,451,683</u>                 | <u>263,782,043</u>   |
| <b>Expenses</b>  |                                     |                     |                                    |                      |
| Cost of services   | 96,828,245                          | 66,736,945          | 281,721,686                        | 192,951,753          |
| General and administrative expenses                                  | 9,032,024                           | 4,380,878           | 31,481,810                         | 15,434,640           |
| Depreciation and amortization  | 4,843,037                           | 4,764,783           | 14,819,627                         | 14,407,113           |
| <b>Total expenses</b>  | <u>110,703,306</u>                  | <u>75,882,606</u>   | <u>328,023,123</u>                 | <u>222,793,506</u>   |
| <b>Income from operations</b>  | <u>56,577,104</u>                   | <u>21,251,675</u>   | <u>86,428,560</u>                  | <u>40,988,537</u>    |
| <b>Other income (expense)</b>  |                                     |                     |                                    |                      |
| Loss from equity method investments                                  | (4,215,056)                         | (1,461,096)         | (2,573,219)                        | (28,936)             |
| Interest expense   | (178,318)                           | (14,984)            | (374,002)                          | (16,370)             |
| Interest income  | 343,369                             | 226,864             | 953,003                            | 618,641              |
| Change in fair value of derivative instruments                       | -                                   | (406,665)           | -                                  | (278,886)            |
| Other income   | 684,283                             | 94,471              | 1,112,935                          | 122,609              |
| <b>Total other income (expense), net</b>                             | <u>(3,365,722)</u>                  | <u>(1,561,410)</u>  | <u>(881,283)</u>                   | <u>417,058</u>       |
| <b>Income before provision for income taxes</b>                      | 53,211,382                          | 19,690,265          | 85,547,277                         | 41,405,595           |
| <b>Provision for income taxes</b>                                    | <u>14,585,942</u>                   | <u>7,865,902</u>    | <u>23,338,589</u>                  | <u>16,491,982</u>    |
| <b>Net income</b>  | 38,625,440                          | 11,824,363          | 62,208,688                         | 24,913,613           |
| Net income attributable to noncontrolling interest                   | 29,519,043                          | 6,203,991           | 48,277,734                         | 12,948,837           |
| <b>Net income attributable to Apollo Medical Holdings, Inc.</b>      | <u>\$ 9,106,397</u>                 | <u>\$ 5,620,372</u> | <u>\$ 13,930,954</u>               | <u>\$ 11,964,776</u> |
| <b>Earnings per share – basic</b>                                    | \$ 0.28                             | \$ 0.22             | \$ 0.43                            | \$ 0.48              |
| <b>Earnings per share – diluted</b>                                  | \$ 0.24                             | \$ 0.20             | \$ 0.37                            | \$ 0.42              |
| <b>Weighted average shares of common stock outstanding-basic</b>     | 32,917,007                          | 25,067,954          | 32,672,793                         | 25,067,954           |
| <b>Weighted average shares of common stock outstanding – diluted</b> | <u>38,387,700</u>                   | <u>28,417,877</u>   | <u>38,010,838</u>                  | <u>28,417,877</u>    |



**Note About Historical Results for Periods Prior to the Merger**

As a result of the merger involving ApolloMed and Network Medical Management (“NMM”) in December 2017 (the “Merger”), NMM is now a wholly-owned subsidiary of ApolloMed. Although ApolloMed was the legal acquirer in the Merger, for accounting purposes, the Merger is treated as a “reverse acquisition,” and NMM is considered the accounting acquirer and ApolloMed is the accounting acquiree. Accordingly, the condensed consolidated financial statements included above and the description of the Company’s results of operations for the three and nine month periods in 2017 reflect the operations of NMM and its consolidated subsidiaries and variable interest entities (“VIEs”) during those periods, and the condensed consolidated financial statements and the description of the Company’s results of operations for the three and nine month periods in 2018 reflect the combined operations of ApolloMed and NMM and its consolidated subsidiaries and VIEs. Because the financial results for the reported periods in 2017 exclude the results of ApolloMed, the foregoing results of operations in 2018 are not directly comparable to the Company’s results of operations in the 2017 periods.

**Note About Consolidated Entities**

The Company consolidates entities in which it has a controlling financial interest. The Company consolidates subsidiaries in which it holds, directly or indirectly, more than 50% of the voting rights, and variable interest entities (“VIEs”) in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including certain VIEs) in the Company’s consolidated entities. The amount of net income attributable to noncontrolling interests is disclosed in the Company’s condensed consolidated statements of income.

**Note About Stockholders’ Equity, Certain Treasury Stock and Earnings Per Share**

As of the date of this press release, 648,705 shares of ApolloMed’s common stock to be issued as part of the Merger are subject to ApolloMed receiving from those former NMM shareholders a properly completed letter of transmittal (and related exhibits) before such former NMM shareholders may receive their pro rata portion of ApolloMed common stock and warrants. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the Merger. The Company’s condensed consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares as of the closing of the Merger.

Shares of ApolloMed’s common stock owned by Allied Physicians of California IPA (d.b.a. Allied Pacific of California IPA), a variable interest entity of the Company, are legally issued and outstanding but excluded from shares of common stock outstanding in the Company’s condensed consolidated financial statements, as such shares are treated as treasury shares for accounting purposes. Such shares, therefore, are not included in the number of shares of common stock outstanding used to calculate the Company’s earnings per share.

**About Apollo Medical Holdings, Inc.**

ApolloMed is a leading physician-centric integrated population health management company, which, together with its subsidiaries, including a Next Generation Accountable Care Organization (“NGACO”), and its affiliated independent practice associations (“IPAs”) and management services organizations (“MSOs”), are working to provide coordinated, outcomes-based high-quality medical care for patients, particularly senior patients and patients with multiple chronic conditions, in a cost-effective manner. ApolloMed focuses on addressing the healthcare needs of its patients by leveraging its integrated health management and healthcare delivery platform that includes NMM (MSO), Apollo Medical Management (MSO), ApolloMed Hospitalists, APA ACO (NGACO), Allied Physicians of California (IPA) and Apollo Care Connect (Digital Population Health Management Platform).. For more information, please visit [www.apollomed.net](http://www.apollomed.net).

---

## **Forward Looking Statements**

*This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements about the Company's continued growth, ability to delivery sustainable long-term value, ability to respond to the changing environment, operational focus, strategic growth plans, and merger integration efforts. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company's management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company's reports to the SEC, including without limitation the risk factors discussed in the Company's Annual Report on Form 10-K filed with the SEC on April 2, 2018.*

### **FOR MORE INFORMATION, PLEASE CONTACT:**

**Warren Hosseinion, M.D.**  
Co-Chief Executive Officer  
Apollo Medical Holdings, Inc.  
(818) 839-5200  
[warrenhoss@apollomed.net](mailto:warrenhoss@apollomed.net)

---